<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">Skin cancer</z:e> risk from the use of immunosuppressive medications used to treat inflammatory conditions is not well understood, though studies clearly establish an exaggerated risk of <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> in solid organ transplant recipients (SOTRs) receiving these medications </plain></SENT>
<SENT sid="1" pm="."><plain>The authors report a patient with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> treated with combination immunosuppressive therapy and common variable <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> developing multiple <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> (<z:mp ids='MP_0004207'>SCCs</z:mp>) of the skin, necessitating adjustment of her immunosuppressive regimen </plain></SENT>
<SENT sid="2" pm="."><plain>As more patients are treated with immunosuppressive medications for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e>, clinicians must be aware of the possible increased risk of <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e> associated with these medications </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">Skin cancer</z:e> risk assessment, screening for sub-clinical <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and frequent skin exams of high risk patients may represent strategies to improve the safety of these medications </plain></SENT>
</text></document>